Factor Xa Inhibitors

Endogenous factors and drugs that inhibit or block the activity of FACTOR XA.

Also Known As:

Direct Factor Xa Inhibitors; Anticoagulant, Direct-Acting Oral; Anticoagulants, Direct-Acting Oral; Direct Acting Oral Anticoagulant; Direct Acting Oral Anticoagulants; Inhibitor, Factor Xa; Oral Anticoagulant, Direct-Acting; Oral Anticoagulants, Direct-Acting; Xa Inhibitor, Factor; Direct Factor Xa Inhibitor; Direct-Acting Oral Anticoagulant; Direct-Acting Oral Anticoagulants; Factor Xa Inhibitor

Networked: 1198 relevant articles (105 outcomes, 236 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Chemical Actions and Uses
- Pharmacologic Actions: 160
  - Therapeutic Uses: 47080
    - Hematologic Agents: 2
      - Anticoagulants: 32414
        Antithrombins: 3501
        Factor Xa Inhibitors: 1198
  - Molecular Mechanisms of Pharmacological Action: 24
    - Enzyme Inhibitors: 1659
      - Protease Inhibitors: 6291
        Serine Proteinase Inhibitors: 1371
        Antithrombins: 3501
        Factor Xa Inhibitors: 1198

Experts

1.	Lip, Gregory Y H: 25 articles (01/2022 - 03/2007)
2.	Connolly, Stuart J: 15 articles (01/2022 - 03/2010)
3.	Büller, Harry R: 14 articles (01/2021 - 11/2002)
4.	Beyer-Westendorf, Jan: 12 articles (01/2022 - 11/2015)
5.	Giugliano, Robert P: 12 articles (03/2019 - 10/2010)
6.	Weitz, Jeffrey I: 12 articles (01/2019 - 03/2005)
7.	Agnelli, Giancarlo: 11 articles (01/2022 - 07/2007)
8.	Fox, Keith A A: 11 articles (01/2022 - 03/2005)
9.	Middeldorp, Saskia: 11 articles (01/2022 - 10/2013)
10.	Verhamme, Peter: 11 articles (01/2021 - 12/2010)

Related Diseases

1.	Hemorrhage 01/01/2023 - "There was also no clear difference between the oral factor Xa inhibitors and conventional anticoagulation in the prevention of recurrent PE (OR 0.92, 95% CI 0.66 to 1.29; 3 studies, 8186 participants; moderate-certainty evidence), recurrent VTE (OR 0.83, 95% CI 0.66 to 1.03; 8 studies, 11,416 participants; moderate-certainty evidence), DVT (OR 0.77, 95% CI 0.48 to 1.25; 2 studies, 8151 participants; moderate-certainty evidence), all-cause mortality (OR 1.16, 95% CI 0.79 to 1.70; 1 study, 4817 participants; moderate-certainty evidence) and major bleeding (OR 0.71, 95% CI 0.36 to 1.41; 8 studies, 11,447 participants; low-certainty evidence); the heterogeneity for major bleeding was significant (I2 = 79%). " 10/01/2022 - "This study demonstrated that PCC used for the treatment of factor Xa inhibitor-associated ICH related to mild TBI did not significantly impact the incidence or degree of hemorrhage progression, and PCC treatment did not result in increased thromboembolic events." 10/01/2022 - "This study seeks to evaluate the impact of reversal with PCC on hemorrhage progression and outcomes in patients with TBI on preinjury factor Xa inhibitors. " 12/01/2021 - "Databases were searched for relevant studies where AA was used to determine efficacy and safety in bleeding patients who were on factor Xa inhibitors. " 09/01/2021 - "Direct-acting oral anticoagulants (DOACs) are increasingly used, with studies showing a lower risk of gastrointestinal bleeding (GIB), but overall data for GIB risk remains debatable. "
2.	Atrial Fibrillation 05/25/2023 - "The efficacy of factor Xa inhibitors in patients with atrial fibrillation (AF) and rheumatic heart disease (RHD) is unknown. " 12/01/2016 - "For these reasons, the European Society of Cardiology and other scientific societies now recommend direct-acting oral anticoagulants as first-line treatment for preventing thromboembolic events in atrial fibrillation." 12/15/2020 - "The objectives of this study were to evaluate efficacy and safety in patients with atrial fibrillation taking direct-acting oral anticoagulants across body mass index (BMI) categories in a contemporary, real-world population. " 11/05/2020 - "Five-Year Trends in Potential Drug Interactions with Direct-Acting Oral Anticoagulants in Patients with Atrial Fibrillation: An Australian-Wide Study." 04/01/2020 - "Several real-world studies have evaluated adherence to direct acting oral anticoagulants in patients with non-valvular atrial fibrillation (NVAF); however, these studies have not been systematically summarized. "
3.	Stroke (Strokes) 01/01/2022 - "This study aimed to assess the net budget impact of direct-acting oral anticoagulants (DOACs) instead of warfarin for stroke prevention in patients with non-valvular AF from the payer's perspective. " 01/01/2023 - "The growing use of factor Xa inhibitors has increasingly caused patients with stroke to be excluded from treatment with IV thrombolysis. " 01/01/2021 - "During this time, the proportion of patients with AF and high stroke risk who were prescribed an OAC rose from 41.7% (95% CI 40.7-42.8%) to 55.2% (95% CI 54.7-55.8%; p for trend < 0.001) with the direct-acting oral anticoagulants accounting for over three-quarters of usage by 2018. " 10/25/2018 - "Measuring anti-Xa activity (AXA) has been reported as useful for predicting future risk of hemorrhagic and ischemic events in stroke patients taking direct factor Xa inhibitors. " 10/25/2018 - "Anti-Xa Activity and Event Risk in Patients With Direct Factor Xa Inhibitors Initiated Early After Stroke."
4.	Venous Thromboembolism 05/01/2022 - "Introduction: Limited data exists on the safety and efficacy of direct-acting oral anticoagulants (DOAC) use in morbidly obese patients with venous thromboembolism (VTE). " 09/30/2023 - "Adherence and persistence to direct factor Xa inhibitors in the community following newly diagnosed venous thromboembolism: a retrospective pharmacy-linkage study." 08/01/2007 - "A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery." 11/23/2023 - "Direct-acting oral anticoagulants (DOACs) have become the preferred drugs for managing venous thromboembolism (VTE). " 01/01/2023 - "New international guidelines now allow for use of direct factor Xa inhibitors both as prophylaxis and treatment for venous thromboembolism. "
5.	Thrombosis (Thrombus) 01/01/2019 - "Efficacy of Direct Acting Oral Anticoagulants in Treatment of Left Ventricular Thrombus." 01/01/2023 - "In small-scale studies, factor Xa inhibitors were able to prevent thrombosis and thrombo-embolic events in patients with mechanical heart valves. " 01/01/2018 - "With randomized clinical trials investigating the optimal antithrombotic regimen in patients with MI who require concomitant chronic anticoagulation and with the emergence of the direct-acting oral anticoagulants, treatment options for post-MI LV thrombus have become more complicated. " 11/12/2002 - "Current phase III trials with this synthetic selective factor Xa inhibitor focus on its use in the treatment of patients with venous and arterial thrombosis. " 04/01/2023 - "Direct acting oral anticoagulants are inferior to VKAs, especially those with triple-positive APS and arterial thrombosis. "

Related Drugs and Biologics

1.	Rivaroxaban
2.	Warfarin (Coumadin)
3.	apixaban
4.	Antithrombins
5.	Anticoagulants
6.	Vitamin K
7.	Dabigatran
8.	Aspirin (Acetylsalicylic Acid)
9.	Heparin (Liquaemin)
10.	edoxaban

Related Therapies and Procedures

1.	Therapeutics
2.	Knee Replacement Arthroplasty (Total Knee Replacement)
3.	Oral Administration
4.	Secondary Prevention
5.	Operative Surgical Procedures